MedPlus Health Q2 Profit Climbs to Rs 560.69 Million

Revenue reached Rs 20,371.08 million for the quarter ended September 30, 2026. Net profit rose sequentially from Rs 331.67 million in the previous quarter.

Reader Takeaway: Strong revenue and sequential profit growth underpin performance, though ESOP dilution remains a standard ongoing corporate activity.

What just happened

MedPlus Health Services has released its financial results for the quarter and half-year ended September 30, 2026. The company posted a consolidated revenue of Rs 20,371.08 million, representing growth over the same period last year (Rs 16,793.29 million). The board has also formally approved the allotment of 19,095 equity shares under the MedPlus Employees Stock Option Plan (ESOP) 2021.

Why this matters

The company’s bottom-line recovery—nearly doubling its net profit sequentially—reflects stable operational execution. The retail division continues to be the dominant engine for the firm, contributing Rs 19,957.68 million in revenue. Investors should note the unmodified review report from statutory auditors, which adds a layer of reliability to these numbers.

Segment Performance

The retail segment remains the primary driver of value, generating a profit of Rs 557.56 million. Meanwhile, the diagnostic services segment contributed Rs 410.54 million in revenue with a segment result of Rs 49.30 million. These figures indicate that while diagnostics is a smaller contributor, it remains profitable.

What to track next

Watch for the company's future updates on expanding the retail pharmacy footprint, which remains the backbone of their operations. Shareholders should also monitor the impact of ongoing ESOP exercises on share dilution and long-term equity structure.